Trial · NCT07318883
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR assessed by BICR (part I) | Assessed up to appoximately 6 months from enrollment | Defined as the proportion of participants who achieve a best overall response of CR or PR |
| Primary | PFS assessed by BICR (part I) | Assessed up to appoximately 16 months from enrollment | Defined as the time from randomization to the first documentation of PD (RECIST v1.1) or death due to any cause (whichever occurs first) |
| Primary | PFS assessed by BICR (part II) | Assessed up to appoximately 23 months from enrollment | Defined as the time from randomization to the first documentation of PD (RECIST v1.1) or death due to any cause (whichever occurs first) |
| Primary | OS (part II) | Assessed up to appoximately 42 months from enrollment | Defined as the time from randomization to death due to any cause |
| Secondary | DCR (part I) | Assessed up to appoximately 6 months from enrollment | Defined as the proportion of participants who achieve a best overall response of CR or PR or an SD |
| Secondary | OS (part I) | Assessed up to appoximately 35 months from enrollment | Defined as the time from randomization to death due to any cause |
| Secondary | DOR (part I) | Assessed up to appoximately 35 months from enrollment | Defined as the time from the first documented objective response to PD or death |
| Secondary | ORR assessed by investigator (part I) | Assessed up to appoximately 6 months from enrollment | Defined as the proportion of participants who achieve a best overall response of CR or PR |
| Secondary | PFS assessed by investigator (part I) | Assessed up to appoximately 16 months from enrollment | Defined as the time from randomization to the first documentation of PD (RECIST v1.1) or death due to any cause (whichever occurs first) |
| Secondary | Incidence of adverse events (part I) | Assessed up to appoximately 35 months from enrollment | |
| Secondary | ORR (part II) | Assessed up to appoximately 6 months from enrollment | Defined as the proportion of participants who achieve a best overall response of CR or PR |
| Secondary | DCR (part II) | Assessed up to appoximately 6 months from enrollment | defined as the proportion of participants who achieve a best overall response of CR or PR or an SD lasting for 12 weeks |
| Secondary | DOR (part II) | Assessed up to appoximately 42 months from enrollment | Defined as the time from the first documented objective response to PD or death |
| Secondary | PFS assessed by investigator (part II) | Assessed up to appoximately 23 months from enrollment | Defined as the time from randomization to the first documentation of PD (RECIST v1.1) or death due to any cause (whichever occurs first) |
| Secondary | Incidence of adverse events (part II) | Assessed up to appoximately 42 months from enrollment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07318883/registered